mail2

Diagnosis

The 2015 consensus diagnostic criteria for NMO and NMO spectrum disorders (NMOSD) apply the latest scientific and medical insights into adult and pediatric disease, imaging, laboratory tests, and potential relationships of NMO/SD to other autoimmune diseases. These new criteria are anticipated to improve diagnostic accuracy of NMO/SD and other autoimmune diseases and speed appropriate therapies.

  1. Advanced from the 2006 NMO Diagnostic Criteria
  2. Authored by the International Panel on Neuromyelitis Optica Diagnosis (IPND)
  3. Sponsored by The Guthy – Jackson Charitable Foundation

Publications

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Review Paper:
"A Decade Later"

 

Download Resources

Full-page Criteria

Quick Reference Card

NMO Resources

The Interview

guthy-jackson-foundation-funded-researchers-dean-wingerchunk-md
guthy-jackson-foundation-funded-researchers-brian-weinshenker-md

The recent release of new diagnostic criteria for neuromyelitis optica spectrum disorders (NMOSD) by the International Panel for Neuromyelitis Optica Diagnosis (IPND) is a critical and exciting step toward a cure for NMO.

Led by Drs. Dean Wingerchuk and Brian Weinshenker from the Mayo Clinic, the IPND was created to identify, critically assess, and integrate the available evidence relevant to the diagnosis of NMO as compared to related diseases.

In this Q&A, the GJCF talks with with Drs. Wingerchuk and Weinshenker, asking them about the new diagnostic criteria and what it means for the future of NMO:

Press Release

Press Release
July 8, 2015

Quick Reference Card

The International Panel on Neuromyelitis Optica Diagnosis (IPND) set out to identify, critically assess, and integrate the available evidence relevant to the diagnosis of NMO as compared to related diseases. During this process, the IPND developed the new 2015 consensus diagnostic criteria for NMO and NMO spectrum disorders (NMOSD). The IPND worked in affiliation with The Guthy-Jackson Charitable Foundation International Clinical Consortium (ICC).

The Panel

The IPND was comprised of the following expert members, each of whom contributed effort within one or more panel subgroups and tasks throughout the process. The Guthy-Jackson Charitable Foundation team coordinated and facilitated the IPND in this important advance.

Dean Wingerchuk, MD, FRCP(C)
Mayo Clinic (Scottsdale, AZ)
Brenda Banwell, MD, FRCP(C)
Children’s Hospital of Philadelphia
Jeffrey Bennett, MD, PhD
University of Colorado Denver
William Carroll, MD
Sir Charles Gairdner Hospital (Australia)
Tanuja Chitnis, MD
Massachusetts General Hospital
Jerome de Seze, MD
Strasbourg University (France)
Kazuo Fujihara, MD
Tohoku University Graduate School of Medicine (Japan)
Benjamin Greenberg, MD
UT Southwestern Medical Center
Anu Jacob, MD
The Walton Centre (United Kingdom)
Sven Jarius, MD
University Hospital Heidelberg (Germany)
Marco Lana-Peixoto, MD, PhD
Federal University of Minas Gerais Medical School (Brazil)
Michael Levy, MD, PhD
Johns Hopkins University
Jack Simon, MD
Portland VA Medical Center and Oregon Health and Sciences University
Silvia Tenembaum, MD
National Pediatric Hospital Dr. Juan P. Garrahan (Argentina)
Anthony Traboulsee, MD
University of British Columbia (Canada)
Patrick Waters, PhD
University of Oxford (United Kingdom)
Brian Weinshenker, MD, FRCP(C)
Mayo Clinic (Rochester, MN)
Philippe Cabre, MD
Centre Hospitalier Universitaire de Fort de France, (Martinique)

NMO-IgG Test Access

ARUP Laboratories
Assay Method: ELISA** Detects anti-AQP4 antibody
Test Code: 2003036
Turn-Around Time: 1 – 8 days
Estimated Cost: Refer to hospital or doctor
www.aruplab.com
(800) 522-2787

 

Athena Diagnostics, Inc.
Assay Method: ELISA** Detects anti-AQP4 antibody
Test Code: 193
Turn-Around Time: 5 – 7 days
Estimated Cost: $840 – Insurance; $560 – Hospital or reference laboratory
www.athenadiagnostics.com
(800) 394-4493

 

BioReference Laboratories
Assay Method: Outsourced to ARUP
Test Code: 6371
Turn-Around Time: 10 business days from date of arrival
Estimated Cost: 395
www.bioreference.com
(800) 522-2787

 

GenPath Diagnostics
Assay Method: Outsourced to ARUP
Test Code: 6371-9
Turn-Around Time: 10 business days from date of arrival
Estimated Cost: 395
www.genpathdiagnostics.com
(800) 633-4522

 

Kaiser Permanente
Assay Method: Outsourced to Quest Diagnostics
Test Code: Members must inquire
Turn-Around Time: Members must inquire
Estimated Cost: Members must inquire
www.kaiserpermanente.org
(800) 464-4000

 

LabCorp
Assay Method: ELISA** Detects anti-AQP4 antibody
Test Code: 4210
Turn-Around Time: 3 – 4 days
Estimated Cost: 764
www.labcorp.com/wps/portal
(800) 859-6046

 

Mayo Clinic
Assay Method: Cell binding Assay (CBA) / Detects IgG Specific for AQP4 by Fluorescence-Activated Cell Sorting (FACS)
Test Codes:
NMOFS: Neuromyelitis Optica (NMO)/Aquaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Assay, Serum
NMOFC: Neuromyelitis Optica (NMO)/Aquaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Assay, Spinal Fluid
Turn-Around Time: 4 – 7 days
Estimated Cost: Based on client pricing. Institutional billing only
www.mayoclinic.org
(800) 533-1710

 

Mayo Clinic
Assay Method: Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay, Serum
Test Codes:
86255
Turn-Around Time: 5 – 8 days
Estimated Cost: Based on client pricing. Institutional billing only
www.mayoclinic.org
(800) 533-1710

 

Mayo Clinic
Assay Method: Cell binding Assay (CBA) / Detects IgG Specific for AQP4 by Fluorescence-Activated Cell Sorting (FACS)
Test Codes:
86255 X2
Turn-Around Time: 7 – 10 days
Estimated Cost: Based on client pricing. Institutional billing only
www.mayoclinic.org
(800) 533-1710

 

Quest Diagnostics
Assay Method: ELISA** Detects anti-AQP4 antibody
Test Code: 90382
Turn-Around Time: 7 – 14 days
Estimated Cost: 560
www.questdiagnostics.com
(877) 291-7521